Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overvalued
On October 06, 2026, Bruker Corp (BRKR) shares fell 5.3% to a current price of $60.50, moving within a 52-week range of $32.37 to $66.98. This drop comes amidst
BRKR - Bruker Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$67.00
DETAILS
HIGH:
$80.00
LOW:
$50.00
MEDIAN:
$70.00
CONSENSUS:
$67.00
UPSIDE:
10.74%
Stock News
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei.
Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bruker (NASDAQ:BRKR) Sets New 1-Year High – Should You Buy?
Bruker Corporation (NASDAQ: BRKR - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $65.48 and last traded at $65.25, with a volume of 222753 shares traded. The stock had previously closed at $64.51. Wall Street Analyst Weigh In BRKR has been the topic of
Neuralink Stock: How to Invest Before the IPO
You can't buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
At the Human Proteome Organization World Congress 2026, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni wor
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis.
Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
Bruker NASDAQ: BRKR CFO Gerald Herman said the company's second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing, including semiconductor-metrology orders that are expected to shift into the fourth quarter.
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley an.
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bruker Corporation to Present at Upcoming Investor Conferences
[url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences:Wells Fargo 21st Annual Heal
Bruker Corporation to Present at Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healthcare Conference in Boston, MA Wednesday, September 9, 2026 at 8:00 a.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York City Wednesday, September 16, 2026, at 10:45 a.m. Eastern Time Bank of America Global Healthcare Conference in London, UK Tuesday, September 22, 2026, at 6:45 a.
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
Bruker Energy and Supercon Technologies (BEST), a segment of [url="]Bruker Corporation[/url] (Nasdaq: BRKR), and Luvata Materials and Solutions, a Business Unit of
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration to support the rapidly growing demand for superconducting materials and technologies required by next-generation magnetic confinement fusion power demonstration plant projects worldwide.The BEST-LUVATA collaboration aims to further strengthen and e.
Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
Deutsche Bank AG Invests $1.44 Million in Bruker Corporation $BRKR
Deutsche Bank AG acquired a new stake in Bruker Corporation (NASDAQ: BRKR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,914 shares of the medical research company's stock, valued at approximately $1,439,000. Other large investors have also
745,079 Shares in Bruker Corporation $BRKR Purchased by Bank of New York Mellon Corp
Bank of New York Mellon Corp acquired a new stake in Bruker Corporation (NASDAQ: BRKR) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 745,079 shares of the medical research company's stock, valued at approximately $44,839,000. Bank of New York Mellon Corp
Handelsbanken Fonder AB Acquires 18,165 Shares of Bruker Corporation $BRKR
Handelsbanken Fonder AB increased its holdings in Bruker Corporation (NASDAQ: BRKR) by 49.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,805 shares of the medical research company's stock after acquiring an additional 18,165 shares during the period. Handelsbanken Fonder
Price Targets
Bruker price target raised to $70 from $58 at Barclays
$70.00
(was $60.50)
Luke Sergott
·
Barclays
Bruker price target raised to $80 from $60 at Leerink
$80.00
(was $63.10)
Leerink Partners
Bruker assumed with a Neutral at UBS
$65.00
(was $58.37)
UBS
Bruker price target raised to $50 from $45 at Stifel
$50.00
(was $50.30)
Stifel Nicolaus
Bruker price target raised to $70 from $50 at Guggenheim
$70.00
(was $60.91)
Subbu Nambi
·
Guggenheim
Bruker price target raised to $60 from $53 at Barclays
$60.00
(was $55.11)
UBS
Bruker price target raised to $45 from $40 at Stifel
$45.00
(was $43.73)
Daniel Arias
·
Stifel Nicolaus
Bruker price target raised to $45 from $40 at UBS
$45.00
(was $42.30)
UBS
Bruker price target raised to $53 from $45 at Barclays
$53.00
(was $42.30)
Luke Sergott
·
Barclays
Bruker price target lowered to $35 from $40 at Goldman Sachs
$35.00
(was $37.19)
Evie Koslosky
·
Goldman Sachs
Bruker price target raised to $49 from $43 at UBS
$49.00
(was $36.99)
UBS
Bruker price target lowered to $50 from $55 at Barclays
$50.00
(was $37.51)
Luke Sergott
·
Barclays
Bruker price target lowered to $50 from $55 at Jefferies
$50.00
(was $37.51)
Jefferies
Bruker price target raised to $58 from $53 at Guggenheim
$58.00
(was $49.02)
Guggenheim
Bruker price target raised to $53 from $45 at Guggenheim
$53.00
(was $49.87)
Subbu Nambi
·
Guggenheim
Bruker price target raised to $55 from $48 at Wells Fargo
$55.00
(was $45.12)
Brandon Couillard
·
Wells Fargo
Bruker price target raised to $55 from $45 at Barclays
$55.00
(was $45.12)
Barclays
Wolfe upgrades Bruker to Outperform on 2026 growth
$60.00
(was $47.65)
Wolfe Research
Bruker initiated with a Sell at Goldman Sachs
$40.00
(was $46.00)
Goldman Sachs
Bruker initiated with a Buy at Rothschild & Co Redburn
$60.00
(was $43.39)
Redburn Partners